Long-acting RSV monoclonal antibodies in infant prophylaxis — the single-injection passive immunization (nirsevimab/Beyfortus) providing five-month protection against RSV lower respiratory tract disease in all infants regardless of gestational age or health status representing the most significant preventive advance in pediatric infectious disease — create the most universally...